Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
31.46
+0.55 (1.78%)
Nov 11, 2026, 1:35 PM EST - Market open
Amylyx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
4.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 11.11B |
| Perrigo Company | 4.09B |
| Amneal Pharmaceuticals | 3.20B |
| Hims & Hers Health | 2.58B |
| Lantheus Holdings | 1.56B |
| Supernus | 1.37B |
| Trulieve Cannabis | 1.08B |
| HUTCHMED (China) | 549.12M |
AMLX News
- 22 hours ago - Amylyx Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 1 day ago - Amylyx price target raised to $39 from $38 at Mizuho - TheFly
- 2 days ago - Amylyx Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 6 days ago - Amylyx Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 6 days ago - Amylyx Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 6 days ago - Amylyx Pharmaceuticals Earnings release: Q3 2026 - Filings
- 6 days ago - Amylyx reports Q3 EPS (38c), consensus (37c) - TheFly
- 6 days ago - Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results - Business Wire